Rallybio

About Rallybio

Rallybio is a clinical-stage biotechnology firm targeting the development and commercialization of therapies for severe and rare diseases. The company was founded in January 2018 by a trio of former Alexion Pharmaceuticals executives: Martin Mackay, Stephen Uden, and Jeffrey Fryer. This founding team brought extensive experience in drug development, particularly in the rare disease sector, from their leadership roles at Alexion and other major pharmaceutical companies like Pfizer and AstraZeneca. Mackay, with over 30 years in R&D, held senior positions at Pfizer, AstraZeneca, and Alexion. Uden's background includes serving as Head of Research at Alexion and leading R&D groups at Wyeth and Novartis in Japan. Fryer, a CPA with a background in corporate tax and finance, served as Chief Tax Officer at Alexion before co-founding Rallybio.

The company's business model is focused on identifying and acquiring promising drug candidates with clear biological rationales and accelerating their development. Rallybio operates by building a portfolio of assets to address significant unmet medical needs, with a long-term strategy of generating revenue through the commercialization of these therapies upon regulatory approval. Since it is in the clinical stage, the company does not yet generate revenue from product sales. Financially, Rallybio secured $37 million in a Series A funding round in 2018 and became a publicly traded entity on the Nasdaq (RLYB) following an initial public offering in July 2021, which raised approximately $80.6 million.

Rallybio's therapeutic pipeline is concentrated on maternal-fetal health, complement dysregulation, hematology, and metabolic disorders. A lead product candidate is RLYB212, a monoclonal antibody for the prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT). FNAIT is a rare condition where a mother's immune system attacks the platelets of her fetus, potentially causing severe bleeding. RLYB212 is designed as a subcutaneous injection for at-risk pregnant women to prevent their immune system from producing these harmful antibodies by clearing fetal platelets from the maternal circulation. Another key clinical-stage program is RLYB116, a small protein inhibitor of complement component 5 (C5). This candidate is being developed to treat various rare diseases driven by complement system dysregulation, where the immune system attacks the body's own cells. By inhibiting C5, RLYB116 aims to reduce inflammation and cell damage. The company is also advancing preclinical programs, including RLYB332 for diseases of iron overload and RLYB114 for certain eye diseases.